Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc.

DAWN·NASDAQ

$21.53

+0.0000%
HealthcareBiotechnology

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

At a Glance

Live Snapshot
Market Cap$2.22B
EPS-1.0400
P/E Ratio-20.70
Earnings Date05/13/2026

dawn

Selling, General and Administrative Expenses

Last Annual Value

120.59M

3-Year CAGR

26%

5-Year CAGR

93%

10-Year CAGR

61%

Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc. Competitors Analysis of Selling, General and Administrative Expenses

DAWN · NASDAQ
CompanySelling, General and Administrative Expenses
CAGR 3Y
CAGR 5Y
CAGR 10Y
120.59M
17.1%33.0%N/A 
159.26M
32.1%39.9%23.8%
35.25M
11.1%18.9%13.3%
29.83M
19.6%39.5%N/A
24.18M
35.6%60.6%N/A
ARVN logo
Arvinas, Inc.
NASDAQ:ARVN
89.40M
-3.8%7.7%39.5%
ERAS logo
Erasca, Inc.
NASDAQ:ERAS
38.55M
0.7%11.3%N/A
92.07M
N/AN/AN/A
0.00
N/AN/AN/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
18.37M
14.7%18.4%12.8%
Day One Biopharmaceuticals, Inc.

Day One Biopharmaceuticals, Inc. Fair Value Envelope

DAWN · NASDAQ

Our analysis suggests that DAWN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $21.53, this represents a potential HIDDEN relative to our calculated worth for Day One Biopharmaceuticals, Inc..

Intrinsic Value
Current Price: $21.53